Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
GSK and Sanofi Push Back on Zantac Worries. Shares Rebounded.
10:49am, Friday, 12'th Aug 2022
After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer. A J.P. Morgan note also calle
Drugmakers' shares tumble on growing investor fears over Zantac litigation
09:12am, Friday, 12'th Aug 2022
CNBC's Julianna Tatelbaum discusses U.S. litigation focused on heartburn drug Zantac.
GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
04:24am, Friday, 12'th Aug 2022
Shares in GSK, Sanofi
Sanofi upped to hold at Deutsche Bank as Zantac fears make a sell 'egregious'
03:41am, Friday, 12'th Aug 2022
Sanofi SNY, -3.94% SAN, +0.25% was upgraded to hold from sell at Deutsche Bank, after the heavy selling over the previous two days on worries about Zantac heartburn medication litigation. The first tr
European shares eke out gains at open as healthcare stocks rebound
03:28am, Friday, 12'th Aug 2022
European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains.
GSK, PFE, SNY Stocks Fall on Zantac Litigation
11:34am, Thursday, 11'th Aug 2022
Source: Willy Barton / Shutterstock.com Investors in GSK (NYSE: GSK ) stock, Pfizer (NYSE: PFE ) and Sanofi (NASDAQ: SNY ) are all feeling the heat today. Reportedly, they're concerned about legal pos
Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms
10:38am, Thursday, 11'th Aug 2022
Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac. The post Pharma Stocks GSK, Sanofi And Haleon Lose Billions As
Drug stocks under pressure over Zantac litigation concerns
10:35am, Thursday, 11'th Aug 2022
Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to discuss alleged concerns that Sanofi and GSK's antacid drug Zantac causes cancer.
GSK, Sanofi and Haleon slump on worries over Zantac litigation
07:18am, Thursday, 11'th Aug 2022
European-listed shares of drugmakers Haleon HLN, -11.81% , GSK GSK, -8.48% and Sanofi SAN, -8.81% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set
China's Innovent Biologics secures over $300 million investment from Sanofi
08:37pm, Thursday, 04'th Aug 2022
Innovent Biologics Inc said on Friday Paris-based Sanofi SA would invest HK$2.42 billion ($307.88 million) in the biopharmaceutical group to jointly develop two cancer drugs in China.
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak
08:00am, Thursday, 04'th Aug 2022
The medicine Siga Technologies developed to combat biowarfare is now being used in the ongoing viral outbreak, and Siga stock has exploded.
Sanofi: Arguably One Of The Most Undervalued Pharma Stocks
01:31am, Friday, 29'th Jul 2022
I am bullish on Sanofi as I see the company undervalued as compared to both the company's financials and competitors (EU pharma peers). Sanofi is a leading global pharmaceutical company, with strong r
Sanofi SA (SNY) CEO Paul Hudson on Q2 2022 Results - Earnings Call Transcript
01:24pm, Thursday, 28'th Jul 2022
Sanofi SA (NASDAQ:SNY ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Jean-Baptiste de Chatillon - EVP & CFO Bill Sibo
Sanofi lifts profit outlook as Dupixent sales surge over 43%
01:33am, Thursday, 28'th Jul 2022
French healthcare group Sanofi lifted its full-year earnings outlook on continued strong sales growth for its bestselling drug Dupixent.
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
12:24pm, Thursday, 14'th Jul 2022
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.
